CJ Bioscience, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer (NCT05877430) | CJ Bioscience, Inc. | 2023-09-11 |
Track CJ Bioscience, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.